An integrated network toxicology and multi-omics study identifies ENO1 as a candidate mediator in benzo[a]pyrene-related gastric cancer progression
Frontiers in Pharmacology · 29.06.2026 · 17
DOI: 10.3389/fphar.2026.1857843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.06.2026. Verfasst von Haixia Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province, Wu Jieping Medical Foundation.
Abstract (Originalsprache)
This study employed an integrative toxicogenomic and multi-omics prioritization approach, combined with preliminary in vitro validation, to identify candidate mediators of benzo [a]pyrene (BaP)-associated gastric cancer progression. A BaP-target-gastric cancer interaction network was constructed by integrating toxicogenomic databases with public transcriptomic datasets. Candidate genes were prioritized using differential expression analysis, network-based screening, LASSO regression, and exploratory artificial neural network modeling. Molecular docking was used to generate an in silico structural hypothesis for possible BaP-ENO1 protein-level interaction, while GO/KEGG enrichment and single-cell RNA sequencing characterized associated biological processes and cellular expression patterns. Integrated analyses prioritized ENO1 as the top BaP-associated candidate in gastric cancer. Single-cell analysis revealed elevated ENO1 expression in gastric cancer epithelial cells and tumor-associated macrophages. In vitro experiments demonstrated that BaP enhanced gastric cancer cell proliferation and migration, effects that were partially attenuated by ENO1 knockdown. Collectively, these findings position ENO1 as a candidate mediator of BaP-associated gastric cancer progression and provide preliminary support for further investigation of the BaP-ENO1 relationship. The study also offers a cross-platform framework for prioritizing candidate targets in environmentally linked cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
- Luzhou Key Laboratory of Molecular Cancer, Luzhou, Sichuan, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan Province
- Wu Jieping Medical Foundation
Zitieren
APA
Liu, H., Di, B., Men, X., Zhu, J., Liu, Y., Luo, J., Wang, J., Xiang, L., & Luo, Y. (2026). An integrated network toxicology and multi-omics study identifies ENO1 as a candidate mediator in benzo[a]pyrene-related gastric cancer progression. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1857843
Vancouver
Liu H, Di B, Men X, Zhu J, Liu Y, Luo J, et al. An integrated network toxicology and multi-omics study identifies ENO1 as a candidate mediator in benzo[a]pyrene-related gastric cancer progression. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1857843
BibTeX
@article{Liu2026,
author = {Liu, Haixia and Di, Binru and Men, Xiaoding and Zhu, Jingzhou and Liu, Yaowen and Luo, Jing and Wang, Jianmei and Xiang, Li and Luo, Yuhao},
title = {An integrated network toxicology and multi-omics study identifies ENO1 as a candidate mediator in benzo[a]pyrene-related gastric cancer progression},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1857843}
}
EUVIMED